Search

Displaying results 5941 - 5950 of 6831 in total
  1. Drug

    Bemegride

    go.drugbank.com/drugs/DB13740
    Experimental

    Bemegride is a CNS stimulant that is used to induce convulsions in experimental animals. It has also been used as a respiratory stimulant and in the treatment of barbiturate overdose.

  2. Drug

    Lulizumab pegol

    go.drugbank.com/drugs/DB15441
    Investigational

    Lulizumab pegol is under investigation in clinical trial NCT02843659 (Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome).

  3. Drug

    NP-6A4

    go.drugbank.com/drugs/DB17599
    Experimental

    NP-6A4 is a peptide designed to specifically bind and activate angiotensin II receptor type 2 (AT2R). It has an Orphan Drug designation from the FDA for pediatric cardiomyopathy.[A258523]

  4. Drug

    Eftansomatropin alfa

    go.drugbank.com/drugs/DB18460
    Investigational

    Eftansomatropin alfa (GX-H9) comprises a recombinant human growth hormone fused to hyFc, a synthetic hybrid Fc fragment.

  5. Drug

    Survodutide

    go.drugbank.com/drugs/DB18989
    Investigational

    Survodutide is under investigation in clinical trial NCT06077864 (A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT

  6. Drug

    AZD8630

    go.drugbank.com/drugs/DB19397
    Investigational

    AZD8630 is an experimental drug under investigation, as described in the Phase I clinical study titled "Randomised, Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics

  7. Drug

    Uproleselan

    go.drugbank.com/drugs/DB14829
    Investigational

    Uproleselan is a novel, specific E-Selectin antagonist under investigation in clinical trial NCT02306291 (Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy

  8. Drug

    KAI-1455

    go.drugbank.com/drugs/DB06064
    Experimental

    In preclinical studies, KAI-1455 showed a dramatic reduction in infarct size when delivered prior to the ischemic insult. … KAI-1455 is a selective epsilon protein kinase C (εPKC) activator designed to reduce ischemic organ injury during procedures where blood supply may be compromised, such as coronary artery bypass grafting

  9. Drug

    Tezacitabine

    go.drugbank.com/drugs/DB06433
    Investigational

    A synthetic purine nucleoside analogue with potential antineoplastic activity.

  10. Drug

    TTP889

    go.drugbank.com/drugs/DB05131
    Investigational

    TTP889 has proven to be effective in preventing clot formation in several animal models of human disease, without any signs of the bleeding associated with traditional anticoagulants.